Euroapi S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EAPIF research report →
Companywww.euroapi.com/en
Euroapi SA develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. The company was incorporated in 2021 and is based in Paris, France.
- CEO
- David Seignolle
- IPO
- 2022
- Employees
- 3,187
- HQ
- Paris, FR
Price Chart
Valuation
- Market Cap
- $147.54M
- P/E
- -0.64
- P/S
- 0.16
- P/B
- 0.17
- EV/EBITDA
- 0.62
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 16.80%
- Op Margin
- -4.23%
- Net Margin
- -24.83%
- ROE
- -24.26%
- ROIC
- -3.40%
Growth & Income
- Revenue
- $847.88M · -7.76%
- Net Income
- $-211,120,897 · -61.65%
- EPS
- $-2.23 · -61.59%
- Op Income
- $1.80M
- FCF YoY
- 215.32%
Performance & Tape
- 52W High
- $3.74
- 52W Low
- $1.27
- 50D MA
- $1.47
- 200D MA
- $2.62
- Beta
- 0.96
- Avg Volume
- 184
Get TickerSpark's AI analysis on EAPIF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EAPIF Coverage
We haven't published any research on EAPIF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EAPIF Report →